Jan 21, 2025
FDA approves first monotherapy use
The FDA approves SPRAVATO® as the first and only monotherapy for treatment-resistant depression in adults.
News & Insurance
Recent updates and Texas coverage.
Insurance is the highest-friction part of starting SPRAVATO®. Here's a clear, current overview of how Texas Medicaid, Medicare, and commercial plans handle coverage — plus the savings programs that can lower out-of-pocket cost.
Recent news
May 1, 2025
Texas Medicaid recognizes monotherapy
Texas Medicaid updated prior-authorization criteria to allow SPRAVATO® as monotherapy, aligning with the new FDA indication.
Oct 1, 2025
F32.3 added to PA criteria
Texas Medicaid added diagnosis code F32.3 (Major depressive disorder, single episode, severe with psychotic features) to esketamine prior-authorization criteria.
Coverage in Texas
Insurance, prior authorization & cost
Because SPRAVATO® is FDA-approved (unlike off-label IV ketamine), it is often covered — subject to prior authorization and medical-necessity criteria. Coverage details vary by payer and plan.
Texas Medicaid
Covers esketamine with prior authorization. Typical requirements include age 18+, a baseline clinical assessment, and no contraindications. As of May 2025, Texas Medicaid recognizes monotherapy use. Specific authorization details can vary by managed-care organization (MCO).
Medicare
Covered under Medicare Part B — the drug and the in-office administration and observation are billed together as a Part B outpatient service, because SPRAVATO® is a REMS drug that can't be dispensed for home use. It is not a Part D drug. Patients typically pay 20% coinsurance after meeting the Part B deductible; Medigap coverage can offset this. Billing uses codes G2082 / G2083.
Commercial insurance
Plans like BCBS of Texas, UnitedHealthcare, Cigna, and Aetna generally cover SPRAVATO® but nearly always require prior authorization. Typical PA requirements include documented failure of two or more antidepressants at adequate dose and duration, a qualifying TRD diagnosis, and treatment in a certified setting. Out-of-pocket varies widely (deductible, copay, coinsurance) — and because induction is frequent (twice weekly for the first four weeks), deductibles are often met early in the year.
Prior Authorization 101
Insurers typically require a documented history of trying at least two different antidepressants at adequate doses and durations without adequate response. Your clinic's intake team usually handles the PA submission — bring records of past antidepressant trials (drug name, dose, duration, outcome) to your first visit to speed things along.
Patient savings & assistance
Commercial / private insurance
SPRAVATO withMe
The J&J withMe program: commercially insured patients may pay as little as $10 per treatment (covering both medication and in-office observation). Requirements: age 18+, commercial/private insurance, no income requirement. Government insurance (Medicare, Medicaid, TRICARE) is not eligible. An annual maximum applies — confirm current details with the program.
Enroll: 844-479-4846(844-4S-WITHME)
Uninsured / underinsured
J&J Patient Assistance Program
A separate program that may provide SPRAVATO® free for up to a year to uninsured or underinsured patients who meet income eligibility requirements. Contact your clinic or the program directly to apply.
Note: The $10 figure applies specifically to commercially insured patients enrolled in the withMe program. Actual out-of-pocket cost varies based on your insurance, deductible, and program eligibility.